Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy

Liknande verk

• Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma
  av: Joshua N. Gustine, et al.
  Utgiven: (2025-06-01)
• Impact of body mass index on anti-BCMA chimeric antigen receptor T-cell therapy outcomes in multiple myeloma
  av: Ruth Choa, et al.
  Utgiven: (2025-12-01)
• Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy
  av: Jessica S. Little, et al.
  Utgiven: (2025-08-01)
• Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy
  av: Masooma Shifa Rana, et al.
  Utgiven: (2026-04-01)
• sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
  av: Katja Seipel, et al.
  Utgiven: (2022-03-01)